Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Akari Therapeutics, Plc (AKTX) has a Wall Street consensus price target of $30.00, based on estimates from 7 covering analysts. With the stock currently trading at $0.24, this represents a potential upside of +12601.1%. The company has a market capitalization of $12.56B.
Analyst price targets range from a low of $30.00 to a high of $30.00, representing a 0% spread in expectations. The median target of $30.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, AKTX trades at a trailing P/E of -0.0x. Analysts expect EPS to grow +100.0% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how AKTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for AKTX is $30, representing 12601.1% upside from the current price of $0.2362. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
AKTX has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $30 implies 12601.1% upside from current levels.
AKTX's current price is $0.2362 with a consensus target of $30 (12601.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $30 for AKTX, while the most conservative target is $30. The consensus of $30 represents the median expectation. These targets typically reflect 12-month expectations.
AKTX is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AKTX stock forecast based on 7 Wall Street analysts shows a consensus price target of $30, with estimates ranging from $30 (bear case) to $30 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on AKTX, with a "Buy" consensus rating and $30 price target (12601.1% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AKTX analyst price targets range from $30 to $30, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $30 consensus represents the middle ground.